



I. Jabin,* G. Revial, M. Pfau and P. Netchitaïlo

Tetrahedron: Asymmetry 13 (2002) 563(4a*R*)-(+)-4a-Methyl-1-[(1*S*)-1-phenyl-ethyl]-3,4,4a,5,6,7-hexahydro-1*H*-quinolin-2-one


E.e. = 100%

 $[\alpha]_D^{20} = +73$ (*c* 1.57, EtOH)


Source of chirality: asymmetric synthesis

Absolute configuration: 4a*R*,1-1*S*Nuria Brugat, Josep Duran, Alfonso Polo,* Julio Real,*
Ángel Álvarez-Larena and J. Francesc Piniella*Tetrahedron: Asymmetry* 13 (2002) 569(2*S*)-(1-Diphenylphosphino-3-benzyloxy)propane-2-thiol

E.e. = 92%


 $[\alpha]_D^{24} = +12.5$ (*c* 0.12, CH₂Cl₂)Source of chirality: benzyl (*S*)-(+)-glycidyl etherNuria Brugat, Josep Duran, Alfonso Polo,* Julio Real,*
Ángel Álvarez-Larena and J. Francesc Piniella*Tetrahedron: Asymmetry* 13 (2002) 569Chloro{(2*S*)-(1-diphenylphosphino-3-benzyloxy)propane-2-thiolato}triphenylphosphine palladium(II)

E.e. = 92%


 $[\alpha]_D^{24} = +19.5$ (*c* 0.09, CH₂Cl₂)Source of chirality: benzyl (*S*)-(+)-glycidyl etherNuria Brugat, Josep Duran, Alfonso Polo,* Julio Real,*
Ángel Álvarez-Larena and J. Francesc Piniella*Tetrahedron: Asymmetry* 13 (2002) 569Bis{(2*S*)-(1-diphenylphosphino-3-benzyloxy)propane-2-thiolato}palladium(II)

E.e. = 92%


 $[\alpha]_D^{24} = +14.0$ (*c* 0.10, CH₂Cl₂)Source of chirality: benzyl (*S*)-(+)-glycidyl ether

 $C_{10}H_{16}O_3$ Isopropyl (3*R*)-3-hydroxycyclohex-1-ene-1-carboxylateE.e.=96% (by GC of *O*-acetylacetate derivative) $[\alpha]_D^{20}=+37$ (*c* 1, MeOH)

Source of chirality: microbial transformation

Absolute configuration: 3*R* $C_{10}H_{18}O_3$ Isopropyl (1*R*,3*R*)-3-hydroxycyclohexane-1-carboxylateE.e.=96% (by GC *O*-acetylacetate derivative) $[\alpha]_D^{20}=-10$ (*c* 1, MeOH)


Source of chirality: microbial reduction

Absolute configuration: 1*R*,3*R* $C_{10}H_{18}O_3$ Isopropyl (1*S*,3*R*)-3-hydroxycyclohexane-1-carboxylate

E.e.=96% (by HPLC on chiral column)


 $[\alpha]_D^{20}=+4$ (*c* 1, MeOH)

Source of chirality: microbial transformation

Absolute configuration: 1*S*,3*R* $C_9H_{14}O_3$ Isopropyl (3*R*)-3-hydroxycyclopent-1-ene-1-carboxylateE.e.=99% (by 2 H NMR in chiral solvent) $[\alpha]_D^{20}=+62$ (*c* 0.7, MeOH)

Source of chirality: microbial transformation

Absolute configuration: 3*R*


 $C_{19}H_{38}O_4N_2Si$

(2S,2S)-(-)-(E)-N-[2-(tert-Butyldimethylsilyloxy)-4-([1,3]dioxolan-2-yl)-but-1-ylidene]-N-(2-methoxymethylpyrrolidin-1-yl)-amine

E.e. >96% (based on parent hydrazone)

 $[\alpha]_D^{26} = -50.1$ (*c* 1.04, CHCl₃)


Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,2*S* $C_{20}H_{42}N_2O_4Si$ (1*R*,2*S*,2*S*)-(-)-N-[2-(tert-Butyldimethylsilyloxy)-4-([1,3]dioxolan-2-yl)-1-methylbutyl]-N-(2-methoxymethylpyrrolidin-1-yl)-amine

E.e. >96% (based on parent hydrazone)

 $[\alpha]_D^{27} = -52.7$ (*c* 1.01, CHCl₃)


Source of chirality: asymmetric synthesis

Absolute configuration: 1*R*,2*S*,2*S* $C_{23}H_{48}N_2O_4Si$ (1*R*,2*S*,2*S*)-(-)-N-[1-{[1-(tert-Butyldimethylsilyloxy)-3-([1,3]dioxolan-2-yl-propyl]pentyl}-N-(2-methoxymethylpyrrolidin-1-yl)-amine

E.e. >96% (based on parent hydrazone)

 $[\alpha]_D^{28} = -75.9$ (*c* 1.48, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: 1*R*,2*S*,2*S* $C_{23}H_{48}N_2O_4Si$ (1*R*,2*S*,2*S*)-(-)-N-[1-tert-Butyl-2-(tert-Butyldimethylsilyloxy)-4-[1,3]dioxolan-2-yl-butyl]-N-(2-methoxymethylpyrrolidin-1-yl)-amine

E.e. >96% (based on parent hydrazone)

 $[\alpha]_D^{30} = -91.4$ (*c* 1.15, CHCl₃)

Source of chirality: asymmetric synthesis



Absolute configuration: 1*R*,2*S*,2*S*

(1*R*,2*S*,2*S*)-(-)-*N*-{1-[1-(*tert*-Butyldimethylsilyloxy)-3-[1,3]dioxolan-2-yl-propyl]-heptyl}-*N*-(2-methoxymethylpyrrolidin-1-yl)-amine

E.e. >96% (based on parent hydrazone)

 $[\alpha]_D^{26} = -99.8$ (*c* 1.03, CHCl₃)


Source of chirality: asymmetric synthesis

Absolute configuration: 1*R*,2*S*,2*S*(1*R*,2*S*,2*S*)-(-)-*N*-{1-[2-(*tert*-Butyldimethylsilyloxy)-4-[1,3]dioxolan-2-yl-1-phenylethylbutyl]-heptyl}-*N*-(2-methoxymethylpyrrolidin-1-yl)-amine(2*R*,3*S*)-(+)-2-Methyl-piperidin-3-ol

E.e. >96% (based on parent hydrazine)

 $[\alpha]_D^{26} = +16.2$ (*c* 0.92, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: 2*R*,3*S*(2*R*,3*S*)-(+)-2-*n*-Butyl-piperidin-3-ol

E.e. >96% (based on parent hydrazine)

 $[\alpha]_D^{26} = +28.6$ (*c* 1.90, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: 2*R*,3*S*

 $C_9H_{19}NO$ (2*R*,*S*)-(+)-2-*t*-Butyl-piperidin-3-ol

E.e. >96% (based on parent hydrazine)

 $[\alpha]_D^{26} = +35.7$ (*c* 1.04, $CHCl_3$)


Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*S* $C_{11}H_{23}NO$ (2*R*,*S*)-(+)-2-*n*-Hexyl-piperidin-3-ol

E.e. >96% (based on parent hydrazine)

 $[\alpha]_D^{26} = +32.7$ (*c* 1.06, $CHCl_3$)


Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*S* $C_{13}H_{19}NO$ (2*R*,*S*)-(+)-2-(2-Phenylethyl)-piperidin-3-ol

E.e. >96% (based on parent hydrazine)


 $[\alpha]_D^{26} = +26.8$ (*c* 1.00, $CHCl_3$)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*S* $C_{29}H_{49}NO_4Sn$ Methyl 2-[(1*S*)-1-[(*tert*-butoxy)carbonylamino]-2-phenylethyl]-2-(2*Z*)-3-tributylstannyl-prop-2-enoate $[\alpha]_D^{20} = -1.6$ (*c* = 1.65, $CHCl_3$)

Source of chirality: L-phenylalanine

Absolute configuration: *S*




C₂₆H₅₁NO₄Sn
Methyl 2-[(1S)-1-[(tert-butoxy)carbonylamino]-2-methylbutyl]-(2Z)-3-tributylstannylyl-prop-2-enoate

[α]_D²² = -32.1 (*c* = 1.00, CHCl₃)

Source of chirality: L-isoleucine

Absolute configuration: *S*




C₂₃H₂₇NO₄
Methyl 2-[(1S)-1-[(tert-butoxy)carbonylamino]-2-phenylethyl]-(2Z)-3-phenylprop-2-enoate

[α]_D²⁰ = +19.4 (*c* = 0.99, CHCl₃)

Source of chirality: L-phenylalanine

Absolute configuration: *S*




C₂₀H₂₉NO₄
Methyl 2-[(1S)-1-[(tert-butoxy)carbonylamino]-2-methylbutyl]-(2Z)-3-phenylprop-2-enoate

[α]_D²² = -45.3 (*c* = 1.00, CHCl₃)

Source of chirality: L-isoleucine

Absolute configuration: *S*




C₂₄H₂₉NO₅
Methyl 2-[(1S)-1-[(tert-butoxy)carbonylamino]-2-phenylethyl]-(2Z)-3-(4-methoxy)phenylprop-2-enoate

[α]_D²² = +17.2 (*c* = 1.04, CHCl₃)

Source of chirality: L-phenylalanine

Absolute configuration: *S*




C₂₁H₃₁NO₅

Methyl 2-{(1S)-1-[{(tert-butoxy)carbonyl}amino]-2-methylbutyl}-(2Z)-3-(4-methoxy)phenylprop-2-enoate

[α]_D²² = -58.2 (*c* = 1.36, CHCl₃)

Source of chirality: L-isoleucine

Absolute configuration: *S*



C₁₃H₁₃NO


(*S*)-5-Methylene-1-(1-phenylethyl)-1,5-dihydro-2*H*-pyrrol-2-one

E.e. >99%

[α]_D²⁰ = -42.9 (*c* 3.2, CHCl₃)

Source of chirality: (*S*)-phenylethylamine

Absolute configuration: *S*



C₁₄H₁₅NO₂


1-[(1*S*,2*R*)-2-Hydroxy-1-methyl-2-phenylethyl]-5-methylene-1,5-dihydro-2*H*-pyrrol-2-one

E.e. >99%

[α]_D²⁰ = +14.5 (*c* 5.5, CHCl₃)

Source of chirality: (1*R*,2*S*)-norephedrine

Absolute configuration: 1*S*,2*R*



C₉H₁₁NO₃


(*S*)-Methyl 2-(2-methylene-5-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)propanoate

E.e. >99%

[α]_D²⁰ = -66.5 (*c* 0.2, CHCl₃)

Source of chirality: (*S*)-alanine methyl ester


Absolute configuration: *S*

 $C_{11}H_{15}NO_3$ (S)-Methyl 3-methyl-2-(2-methylene-5-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)butanoate

E.e. >99%

 $[\alpha]_D^{20} = -20.4$ (*c* 4.3, CHCl₃)


Source of chirality: (S)-valine methyl ester

Absolute configuration: *S* $C_{16}H_{17}NO_4$ (S)-Ethyl 3-(4-hydroxyphenyl)-2-(2-methylene-5-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)propanoate

E.e. >99%

 $[\alpha]_D^{20} = -15.6$ (*c* 3.0, CHCl₃)


Source of chirality: (S)-tyrosine ethyl ester

Absolute configuration: *S* $C_{11}H_{13}NO_5$ (S)-Dimethyl 2-(2-methylene-5-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)succinate

E.e. >99%



 $[\alpha]_D^{20} = -53.9$ (*c* 1.0, CHCl₃)

Source of chirality: (S)-glutamic acid diethyl ester

Absolute configuration: *S* $C_9H_{11}NO_4$ (S,RS)-Methyl 7a-methyl-5-oxo-2,3,5,7a-tetrahydropyrrolo[2,1-*b*][1,3]-oxazole-3-carboxylate $[\alpha]_D^{20} = -77.5$ (*c* 0.2, CHCl₃)

Source of chirality: (S)-serine methyl ester

Absolute configuration: *S,RS*




(R)-6,6'-Bis(chlorodimethylsilyl)-2,2'-di(hexyloxy)-1,1'-binaphthyl

E.e. >99%

 $[\alpha]_D^{25} = +37.8$ ($c = 1.08$, CH_2Cl_2)

Source of chirality: (R)-2,2'-dihydroxy-1,1'-binaphthyl

Absolute configuration: R





(R)-6,6'-Bis(chlorodimethylsilyl)-2,2'-di(hexyloxy)-1,1'-binaphthyl

E.e. >99%

 $[\alpha]_D^{25} = -2.1$ ($c = 1.35$, THF)

Source of chirality: (R)-2,2'-dihydroxy-1,1'-binaphthyl

Absolute configuration: R





(R)-6,6'-Bis(dimethylsilyl)-2,2'-di(methoxyethoxymethoxy)-1,1'-binaphthyl

E.e. >99%

 $[\alpha]_D^{25} = +1.9$ (THF, $c = 0.572$)

Source of chirality: (R)-2,2'-dihydroxy-1,1'-binaphthyl

Absolute configuration: R



(R)-6,6'-Bis(dimethylsilyl)-2,2'-binaphtho-20-crown-6

E.e. >99%


 $[\alpha]_D^{25} = -5.2$ (THF, $c = 0.461$)

Source of chirality: (R)-2,2'-dihydroxy-1,1'-binaphthyl

Absolute configuration: R

Patricia T. Baraldi, Paulo H. G. Zarbin, Paulo C. Vieira
and Arlene G. Corrêa*

Tetrahedron: Asymmetry 13 (2002) 621



Ethyl (S)-3-hydroxy-5-methyl-hexanoate

E.e. = 99%


[α]_D²⁵ = -9.95 (c 12.72, CHCl₃)

Source of chirality: microbiological reduction

Absolute configuration: (3S)

Patricia T. Baraldi, Paulo H. G. Zarbin, Paulo C. Vieira
and Arlene G. Corrêa*

Tetrahedron: Asymmetry 13 (2002) 621



(S)-5-Methylhexane-1,3-diol

E.e. = 99%



[α]_D²⁵ = -16.3 (c 1.9, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (3S)

Patricia T. Baraldi, Paulo H. G. Zarbin, Paulo C. Vieira
and Arlene G. Corrêa*

Tetrahedron: Asymmetry 13 (2002) 621



(S)-3-Hydroxy-5-methylhexyl-p-toluenosulfonate

E.e. = 99%


[α]_D²⁵ = -5.2 (c 0.4, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (3S)

Alberto Avenoza,* José I. Barriobero, Jesús H. Busto,
Carlos Cativiela and Jesús M. Peregrina*

Tetrahedron: Asymmetry 13 (2002) 625



Methyl (1S,2S,4R,2'R)-N-(tert-butoxycarbonyl)-2-[2'-methoxy-2'-(trifluoromethyl)phenylacetoxy]-7-azabicyclo[2.2.1]heptane-1-carboxylate

E.e. >95%


[α]_D²⁵ = +45.3 (c 1.09, MeOH)

Source of chirality: resolution

Absolute configuration: 1S,2S,4R,2'R

Alberto Avenoza,* José I. Barriobero, Jesús H. Busto,
Carlos Cativiela and Jesús M. Peregrina*

Tetrahedron: Asymmetry 13 (2002) 625




E.e. >95%
 $[\alpha]_D^{25} = -7.4$ (*c* 1.07, MeOH)
 Source of chirality: resolution
 Absolute configuration: 1*R*,2*R*,4*S*,2*R*




Methyl (1*R*,2*R*,4*S*,2*R*)-*N*-(*tert*-butoxycarbonyl)-2-[2'-methoxy-2'-(trifluoromethyl)phenylacetoxy]-7-azabicyclo[2.2.1]heptane-1-carboxylate

Alberto Avenoza,* José I. Barriobero, Jesús H. Busto,
Carlos Cativiela and Jesús M. Peregrina*

Tetrahedron: Asymmetry 13 (2002) 625



E.e. >95%
 $[\alpha]_D^{25} = +10.6$ (*c* 1.00, MeOH)
 Source of chirality: resolution
 Absolute configuration: 1*S*,2*S*,4*R*




Methyl (1*S*,2*S*,4*R*)-*N*-(*tert*-butoxycarbonyl)-2-hydroxy-7-azabicyclo[2.2.1]heptane-1-carboxylate

Alberto Avenoza,* José I. Barriobero, Jesús H. Busto,
Carlos Cativiela and Jesús M. Peregrina*

Tetrahedron: Asymmetry 13 (2002) 625




E.e. >95%
 $[\alpha]_D^{25} = +14.7$ (*c* 1.00, MeOH)
 Source of chirality: resolution
 Absolute configuration: 1*R*,2*S*,4*R*



(1*R*,2*S*,4*R*)-*N*-(*tert*-Butoxycarbonyl)-2-hydroxy-1-hydroxymethyl-7-azabicyclo[2.2.1]heptane

Alberto Avenoza,* José I. Barriobero, Jesús H. Busto,
Carlos Cativiela and Jesús M. Peregrina*


Tetrahedron: Asymmetry 13 (2002) 625



E.e. >95%
 $[\alpha]_D^{25} = +1.8$ (*c* 0.97, CHCl₃)
 Source of chirality: resolution
 Absolute configuration: 1*S*,4*R*



(1*S*,4*R*)-*N*-(*tert*-Butoxycarbonyl)-7-azabicyclo[2.2.1]heptan-2-one-1-carboxylic acid



C₁₁H₁₇NO₃


(1*S*,4*R*)-*N*-(*tert*-Butoxycarbonyl)-7-azabicyclo[2.2.1]heptan-2-one

E.e. >95%

[α]_D²⁵ = +71.5 (*c* 1.03, CHCl₃)

Source of chirality: resolution

Absolute configuration: 1*S*,4*R*



C₇H₁₂ClNO₃


(1*S*,2*S*,4*R*)-2-Hydroxy-7-azabicyclo[2.2.1]heptane-1-carboxylic acid hydrochloride

E.e. >95%

[α]_D²⁵ = +31.0 (*c* 1.00, H₂O)

Source of chirality: resolution

Absolute configuration: 1*S*,2*S*,4*R*



C₁₃H₁₉NO₅


Methyl (1*S*,4*R*)-*N*-(*tert*-Butoxycarbonyl)-7-azabicyclo[2.2.1]heptan-2-one-1-carboxylate

E.e. >95%

[α]_D²⁵ = -7.2 (*c* 1.11, MeOH)

Source of chirality: resolution

Absolute configuration: 1*S*,4*R*



C₁₃H₂₁NO₅

Methyl (1*S*,2*R*,4*R*)-*N*-(*tert*-Butoxycarbonyl)-2-hydroxy-7-azabicyclo[2.2.1]heptane-1-carboxylate

E.e. >95%


[α]_D²⁵ = -3.4 (*c* 0.87, MeOH)

Source of chirality: resolution and stereoselective reaction

Absolute configuration: 1*S*,2*R*,4*R*

Alberto Avenoza,* José I. Barriobero, Jesús H. Busto,
Carlos Cativiela and Jesús M. Peregrina*

Tetrahedron: Asymmetry 13 (2002) 625



C₇H₁₂ClNO₃
(1*S*,2*R*,4*R*)-2-Hydroxy-7-azabicyclo[2.2.1]heptane-1-carboxylic acid hydrochloride

E.e. >95%

[α]_D²⁵ = -7.1 (*c* 1.06, H₂O)

Source of chirality: resolution and stereoselective reaction

Absolute configuration: 1*S*,2*R*,4*R*

Eugenius Butkus,* Albinas Žilinskas, Sigitas Stončius,
Ričardas Rozenbergas, Marie Urbanová, Vladimír Setnička,
Petr Bouř and Karel Volka

Tetrahedron: Asymmetry 13 (2002) 633



C₉H₁₀O₂
(1*R*,3*R*,6*R*,8*R*)-Tricyclo[4.3.0.0^{3,8}]nonane-4,5-dione

E.e. = 95%

[α]_D¹⁶ = +207.5 (*c* 0.07, CHCl₃)


CD: λ_{max} ($\Delta\epsilon/\text{dm}^3 \text{ mol}^{-1} \text{ cm}^{-1}$) < 235 (positive),
279 (-1.26), 419 (+0.78)

Source of chirality: enantiospecific synthesis

Absolute configuration: 1*R*,3*R*,6*R*,8*R* (assigned by
CD spectroscopy and chemical correlation)

Eugenius Butkus,* Albinas Žilinskas, Sigitas Stončius,
Ričardas Rozenbergas, Marie Urbanová, Vladimír Setnička,
Petr Bouř and Karel Volka

Tetrahedron: Asymmetry 13 (2002) 633



C₁₁H₁₄O₄
(+)-(1*R*,2*R*,4*R*,5*R*)-endo,endo-Dimethyl-bicyclo[2.2.1]heptane-2,5-dicarboxylate

E.e. = 95%


[α]_D²¹ = +32.5 (*c* 0.08, CHCl₃)

Source of chirality: enantiospecific synthesis

Absolute configuration: 1*R*,2*R*,4*R*,5*R* (assigned by
chemical correlation)

Eugenius Butkus,* Albinas Žilinskas, Sigitas Stončius,
Ričardas Rozenbergas, Marie Urbanová, Vladimír Setnička,
Petr Bouř and Karel Volka

Tetrahedron: Asymmetry 13 (2002) 633




C₁₁H₁₄O₄
(+)-(1*R*,2*S*,4*R*,5*S*)-exo,exo-Dimethyl-bicyclo[2.2.1]heptane-2,5-dicarboxylate

E.e. = 95%

[α]_D¹⁶ = +40.0 (*c* 0.1, CHCl₃)

Source of chirality: enantiospecific synthesis

Absolute configuration: 1*R*,2*S*,4*R*,5*S* (assigned by
chemical correlation)



C₁₁H₁₂O₄S


(2S,3S,4E)-5-Benzenesulfonyl-2,3-epoxy-pent-4-en-1-ol

E.e., d.e. >95% (NMR)

[α]_D²⁰ = -11.7 (*c* = 1.90, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*S*



C₁₈H₁₈O₆S₂

(2S,3S,4E)-5-Benzenesulfonyl-2,3-epoxy-pent-4-en-1-yl tosylate

E.e., d.e. >95% (NMR)

[α]_D²⁰ = -12.2 (*c* = 0.78, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*S*



C₁₃H₁₁F₃O₃S


(2S,3S,4E)-5-Benzenesulfonyl-2,3-epoxy-pent-4-en-1-yl trifluoroacetate

E.e., d.e. >95% (NMR)

[α]_D²⁰ = -20.5 (*c* = 0.92, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*S*



C₁₃H₁₄O₅S


(2S,3S,4E)-5-Benzenesulfonyl-2,3-epoxy-pent-4-en-1-yl acetate

E.e., d.e. >95% (NMR)

[α]_D²⁰ = -40.6 (*c* = 1.17, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*S*




C₁₄H₁₈O₅S
(2R,3S,4E)-5-Benzenesulfonyl-1,2-isopropylidenedioxy-pent-4-en-ol

E.e., d.e. >95% (NMR)

[α]_D²⁰ = +11.3 (*c* = 0.60, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*S*




C₂₁H₂₄O₅S₂
(2S,3R,4E)-5-Benzenesulfonyl-2,3-isopropylidenedioxy-pent-4-en-1-yl tosylate

E.e., d.e. >95% (NMR)

[α]_D²⁰ = +3.8 (*c* = 1.05, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*R*




C₂₆H₂₇F₃O₆S
(2S,3R,4E)-5-Benzenesulfonyl-2,3-isopropylidenedioxy-pent-4-en-1-yl trifluoroacetate

E.e., d.e. >95% (NMR)

[α]_D²⁰ = +4.3 (*c* = 0.15, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*R*




C₂₆H₂₀O₆S
(2R,3S,4E)-5-Benzenesulfonyl-2,3-isopropylidenedioxy-pent-4-en-1-yl acetate

E.e., d.e. >95% (NMR)

[α]_D²⁰ = -5.0 (*c* = 0.42, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*S*




C₂₄H₂₈O₅S
(2R,3R,4S)-2-Benzenesulfonylmethyl-3,4-isopropylidenedioxy-tetrahydrofuran

E.e., d.e. >95% (NMR)

[α]_D²⁰ = +18.0 (*c* = 0.25, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*R*,4*S*




C₂₄H₂₈O₅S
(2R,3S,4R)-2-Benzenesulfonylmethyl-3,4-isopropylidenedioxy-tetrahydrofuran

E.e., d.e. >95% (NMR)

[α]_D²⁰ = -14.0 (*c* = 0.26, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*S*,4*R*




C₂₁H₂₅NO₄S
(2R,3R,4S)-*N*-Benzyl-2-benzenesulfonylmethyl-3,4-isopropylidenedioxypyrrolidine

E.e., d.e. >95% (NMR)

[α]_D²⁰ = +40.2 (*c* = 0.94, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*S*,4*R*



C₁₁H₁₄O₅S
(2S,3R,4R)-2-Benzenesulfonylmethyl-tetrahydrofuran-3,4-diol

E.e., d.e. >95% (NMR)


[α]_D²⁰ = -2.1 (*c* = 0.68, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*R*,4*R*

David Díez,* M. Templo Beneitez, Isidro S. Marcos, N. M. Garrido, P. Basabe and Julio G. Urones

Tetrahedron: Asymmetry 13 (2002) 639



C₁₅H₂₁NO₂
(2S,3R,4S)-N-Benzyl-3,4-isopropylidenedioxy-2-methylpyrrolidine

E.e., d.e. >95% (NMR)


[α]_D²⁰ = +33.4 (*c* = 0.70, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*R*,4*S*

David Díez,* M. Templo Beneitez, Isidro S. Marcos, N. M. Garrido, P. Basabe and Julio G. Urones

Tetrahedron: Asymmetry 13 (2002) 639



C₅H₁₀O₃
(2S,3S,4S)-2-Methyl-tetrahydrofuran-3,4-diol

E.e., d.e. >95% (NMR)


[α]_D²⁰ = +8.0 (*c* = 0.50, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*S*,3*S*,4*S*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau, Jeremy C. Prodger and Hitesh J. Sangane

Tetrahedron: Asymmetry 13 (2002) 647



C₅H₉NO₂
(5*S*)-5-Hydroxymethyl-pyrrolidin-2-one


[α]_D²² = +31.8 (*c* 5.0, EtOH)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *S*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau, Jeremy C. Prodger and Hitesh J. Sangane

Tetrahedron: Asymmetry 13 (2002) 647



C₁₈H₃₅NO₃Si
(5*S*)-(tert-Butyl-dimethylsiloxymethyl)-1-(2,2-dimethyl-propionyl)-3,3-dimethyl-pyrrolidin-2-one



[α]_D²⁷ = -41.0 (*c* 0.8, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *S*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



(5*S*)-1-(2,2-Dimethylpropionyl)-3,3-dimethyl-5-trityloxymethyl-pyrrolidin-2-one


[α]_D²² = -44.0 (*c* 0.5, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *S*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



(5*S*)-1-Aza-2,2-dimethyl-3-oxa-8-oxo-bicyclo[3.3.0]octane


[α]_D²⁵ = +114.7 (*c* 1.0, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *S*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



Methyl (*R*)-2-benzyl-propionate


[α]_D²⁵ = +34.5 (*c* 0.8, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *R*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



(5*S*)-1-Aza-2,2-dimethyl-7,7-dimethyl-3-oxa-8-oxo-bicyclo[3.3.0]octane


[α]_D²⁵ = +75.3 (*c* 1.0, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *S*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₈H₂₀O₂

Benzyl (S)-2-benzyl-propionate


[α]_D²⁵ = +25.7 (c 0.8, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: S

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₇H₁₃NO₂

(5S)-3,3-Dimethyl-5-hydroxymethyl-pyrrolidin-2-one


[α]_D²⁵ = +82.6 (c 1.0, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: S

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₄H₁₉NO₄S

(5S)-O-p-Toluenesulfynylmethyl-3,3-dimethyl-5-pyrrolidin-2-one


[α]_D²⁵ = +21.6 (c 0.5, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: S

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₇H₁₂BrNO

(5S)-5-Bromomethyl-3,3-dimethyl-pyrrolidin-2-one


[α]_D²⁵ = +25.4 (c 1.0, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: S

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₃H₂₇NO₂Si
(5*S*)-(+)-5-*tert*-Butyldimethylsiloxyethyl-3,3-dimethyl-pyrrolidin-2-one


[α]_D²² = +46.8 (*c* 1.0, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *S*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₂₆H₂₇NO₂
(5*S*)-(+)-3,3-Dimethyl-5-trityloxymethyl-pyrrolidin-2-one


[α]_D²⁴ = +10.6 (*c* 0.5, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *S*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₈H₁₅NO
(5*R*)-(-)-5-Ethyl-3,3-dimethyl-pyrrolidin-2-one


[α]_D²² = -28.0 (*c* 2.0, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *R*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₁H₁₄O₃
(2*R*,3*R*)-3-Hydroxy-2-methyl-3-phenylpropionic acid


[α]_D²¹ = +26.8 (*c* 0.5, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: 2*R*,3*R*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₇H₂₃NO₃
(2'R,3'R,5R)-1-(3'-Hydroxy-2'-methyl-3'-phenyl-1'-oxopropyl)-3,3-dimethyl-2-pyrrolidinone


[α]_D²¹ = -26.9 (*c* 0.7, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: 2'R,3'R,5R

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₀H₁₂O₂
(S)-2-Benzyl-propanoic acid


[α]_D²⁵ = +28.6 (*c* 1.0, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: S

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₈H₂₅NO₂
(2'R,5R)-1-(1'-Oxopropyl-2'-phenylmethyl)-5-ethyl-3,3-dimethyl-pyrrolidin-2-one


[α]_D²⁵ = -86.4 (*c* 0.9, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: 2'R,5R

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₈H₂₅NO₂
(2'S,5R)-1-(1'-Oxopropyl-2'-phenylmethyl)-5-ethyl-3,3-dimethyl-pyrrolidin-2-one


[α]_D²⁵ = -42.3 (*c* 0.6, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: 2'S,5R

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₇H₂₃NO₂
(2'R,5R)-1-(1'-Oxopropyl-2'-phenylmethyl)-3,3-dimethyl-5-methyl-pyrrolidin-2-one


[α]_D²⁵ = -76 (c 0.6, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: 2'R,5R

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₇H₂₃NO₂
(2'S,5R)-1-(1'-Oxopropyl-2'-phenylmethyl)-3,3-dimethyl-5-methyl-pyrrolidin-2-one


[α]_D²⁵ = -20.0 (c 0.6, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: 2'S,5R

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₇H₂₃NO₂
(5R)-1-(1'-Oxopropyl-3'-phenyl)-5-ethyl-3,3-dimethyl-pyrrolidin-2-one


[α]_D²⁵ = -71.2 (c 0.53, CH₂Cl₂)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: R

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₁H₁₉NO₂
(5R)-1-(1'-Oxopropyl)-5-ethyl-3,3-dimethyl-pyrrolidin-2-one


[α]_D²⁵ = -121.2 (c 0.8, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: R

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₆H₂₁NO₂
(5*R*)-1-(1'-Oxopropyl-3'-phenyl)-5-methyl-3,3-dimethyl-pyrrolidin-2-one


[α]_D²⁵ = -64 (*c* 0.5, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *R*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₀H₁₇NO₂
(5*R*)-1-(1'-Oxopropyl)-5-methyl-3,3-dimethyl-2-pyrrolidinone


[α]_D²⁵ = -101 (*c* 0.5, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *R*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₃₅H₃₅NO₃
(5*S*)-3,3-Dimethyl-5-triphenylmethoxymethyl-1-(1'-phenylpropionyl)-pyrrolidin-2-one


[α]_D²⁵ = -43.3 (*c* 0.15, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *S*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₂₉H₃₁NO₃
(5*S*)-3,3-Dimethyl-5-triphenylmethoxymethyl-1-propionyl-pyrrolidin-2-one


[α]_D²⁵ = -77.7 (*c* 0.09, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *S*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₂₂H₃₅NO₃Si
(5*S*)-(tert-Butyldimethylsilyloxymethyl)-3,3-dimethyl-1-(3-phenylpropionyl)-pyrrolidin-2-one


[α]_D²⁵ = -68.5 (*c* 0.2, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *S*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₆H₃₁NO₂
(5*S*)-tert-Butyldimethylsilyloxymethyl-3,3-dimethyl-1-propionyl-pyrrolidin-2-one


[α]_D²⁴ = -78.6 (*c* 0.5, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *S*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647



C₁₃H₂₃NO₂
(5*R*)-1-(2',2'-Dimethyl-1'-oxopropyl)-5-ethyl-3,3-dimethyl-pyrrolidin-2-one


[α]_D²¹ = -3.0 (*c* 0.4, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *R*

Stephen G. Davies,* Darren J. Dixon, Gilles J.-M. Doisneau,
Jeremy C. Prodger and Hitesh J. Sanganee

Tetrahedron: Asymmetry 13 (2002) 647




C₁₂H₂₁NO₂
(5*R*)-1-(2',2'-Dimethyl-1'-oxopropyl)-5-methyl-3,3-dimethyl-pyrrolidin-2-one

[α]_D²² = +9.0 (*c* 0.5, CHCl₃)

Source of chirality: (S)-pyroglutamic acid

Absolute configuration: *R*


 $C_5H_6O_2$

(R)-4-Hydroxy-3-cyclopent-2-en-1-one

E.e. = 98%

 $[\alpha]_D^{20} = +78$ (*c* 1.2, CHCl₃)

Source of chirality: enzyme-catalyzed hydrolysis


Absolute configuration: *R* $C_8H_{10}O_4$

(S)-5-Acetoxy-3-methoxycyclopent-2-en-1-one

E.e. >97%

 $[\alpha]_D^{20} = +29$ (*c* 1.6, CHCl₃)

Source of chirality: enzyme-catalyzed hydrolysis

Absolute configuration: *S* $C_6H_8O_3$

(S)-5-Hydroxy-3-methoxycyclopent-2-en-1-one

E.e. >98%

 $[\alpha]_D^{20} = -18$ (*c* 0.5, CHCl₃)

Source of chirality: enzyme-catalyzed hydrolysis

Absolute configuration: *S*